StockIQ.techAstellas Pharma Inc. (4503.T) Stock Analysis
Free AI-powered analysis and research for Astellas Pharma Inc. stock
Sector: Healthcare
4503.T snapshot
Data as of 2 Nov 2026 close. Updated daily.
Astellas Pharma Inc. scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 86% of its 52-week range, up 50.8% over the past year. Latest reported figures show a profit margin of 16.0%, return on equity of 21.3% and revenue growth of +26.7%.
What is driving the score
- Strong Uptrend: +11
- MACD Bullish: +8
- Low P/E (12.3): +10
- Strong Revenue Growth (26.7%): +8
- Good Profit Margin (16.0%): +5
- Weak Liquidity (1.20 Current Ratio): -5
- Excellent ROE (21.3%): +8
- Strong Long-term Uptrend: +8
- Strong Rise (+50.8% over 1 year): +10
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 4503.T report
Astellas Pharma Inc. (4503.T) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 4503.T Now →📰 Latest Update
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Mon, May 18, 2026 at 3:34 PM UTC 2 min read
A recent market research report forecasts significant growth in the hepatic cirrhosis market from 2026 to 2036, highlighting key players such as Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion. This information is crucial for investors as it indicates potential opportunities in the pharmaceutical sector, particularly for companies involved in liver disease treatments. The anticipated market expansion could drive revenue growth and enhance stock performance for these firms.